SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-19-006217
Filing Date
2019-01-11
Accepted
2019-01-10 18:16:34
Documents
3
Group Members
BLACKSTONE CLARUS III L.L.C.BLACKSTONE GROUP L.P.BLACKSTONE GROUP MANAGEMENT L.L.C.BLACKSTONE HOLDINGS I/II GP INC.BLACKSTONE HOLDINGS II L.P.CLARUS VENTURES III GP, L.P.CLARUS VENTURES III, LLCDENNIS HENNERKURT WHEELERNICHOLAS GALAKATOSNICHOLAS SIMONROBE

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO SCHEDULE 13D d676895dsc13da.htm SC 13D/A 249152
2 EX-99.2 d676895dex992.htm EX-99.2 21945
3 EX-99.3 d676895dex993.htm EX-99.3 6401
  Complete submission text file 0001193125-19-006217.txt   279551
Mailing Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142
Business Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142 617-949-2200
Clarus Lifesciences III, L.P. (Filed by) CIK: 0001597143 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1214
Type: SC 13D/A

Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Subject) CIK: 0001633932 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: SC 13D/A | Act: 34 | File No.: 005-88939 | Film No.: 19521117
SIC: 2834 Pharmaceutical Preparations